Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd., has received approval from the FDA and China’s National Medical Products Administration (NMPA) to conduct clinical trials with SIM-0500 in patients with relapsed or refractory multiple myeloma.
Transcode Therapeutics Inc. has reported promising proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics AG.
Eilean Therapeutics LLC has announced clearance by the Human Research Ethics Committee in Australia for a first-in-human phase I trial of balamenib (ZE63-0302), an oral small-molecule inhibitor of the menin-KMT2A interaction.
The small-molecule steroid sulfatase (STS) inhibitor STX-64 (ONESTX-1, irosustat) previously showed a good safety and tolerability profile in several phase I and II clinical trials that evaluated the candidate for oncology indications.
Work was conducted at the University of Bialystok to study plasma galectins (1, 2 and 12) plus serum and urinary levels of tumor necrosis factor (TNF), endothelin-1 (ET-1) and α1-acid-glycoprotein (α1AGP) in regards to the relationship between psoriasis and its related complications.
Recent findings have suggested GAL-201 from Galimedix Therapeutics Inc. is a robust oral candidate to treat Alzheimer’s disease (AD). GAL-201 binds to the misfolded form of amyloid-β (Aβ) monomers, thus preventing its aggregation and formation of neurotoxic oligomers and protofibrils.
Researchers from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and affiliated organizations published preclinical data for a new class of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors being developed as candidates for the treatment of lymphoma.
The third day of the AD/PD 2024 conference in Lisbon started with a plenary lecture given by Professor Howard Fillit entitled, “Translating the biology of aging into new therapeutics for Alzheimer’s disease.” Fillit, a recognized neuroscientist and geriatrician, and co-founder of the Alzheimer’s Drug Discovery Foundation (ADDF), pointed to the geroscience hypothesis which postulates that targeting aging processes may result in preventive and therapeutic options for diseases of old age, including Alzheimer’s disease (AD).
Kymera Therapeutics Inc. has described proteolysis targeting chimeras (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently linked to a cyclin-dependent kinase 2 (CDK2)-targeting moiety through a linker.
RSS
